Objective： In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene （rAd-p53） injection in patients with advanced non-small-cell lung cancer ...Objective： In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene （rAd-p53） injection in patients with advanced non-small-cell lung cancer （NSCLC） in the combination with the therapy of bronchial arterial infusion （BAI）. Methods： A total of 58 patients with advanced NSCLC were enrolled in a non-randomized, two-armed clinical trial. Of which, 19 received a combination treatment of BAI and rAd-p53 （the combo group）, while the remaining 39 were treated with only BAI （the control group）. Patients were followed up for 12 months, with safety and local response evaluated by the National Cancer lnstitute＇s Common Toxicity Criteria and response evaluation criteria in solid tumor （RECIST）, respectively. Time to progression （TTP） and survival rates were also analyzed by Kaplan-Meier method. Results In the combo group, 19 patients received a total of 49 injections ofrAd-p53 and 46 times of BAI, respectively, while 39 patients in the control group received a total of 113 times of BAI. The combination treatment was found to have less adverse events such as anorexia, nausea and emesis, pain, and leucopenia （P〈0.05） but more arthralgia, fever, influenza-like symptom, and myalgia （P〈0.05）, compared with the control group. The overall response rates （complete response （CR）＋partial response （PR）） were 47.3% and 38.4% for the combo group and the control group, respectively （P〉0.05）. Patients in the combo group had a longer TTP than those in the control group （a median 7.75 vs 5.5 months, P-0.018）. However, the combination treatment did not lead to better survival, with survival rates at 3, 6, and 12 months in the combo group being 94.74%, 89.47%, and 52.63%, respectively, com- pared with 92.31%, 69.23%, and 38.83% in the control group （P=0.224）. Conclusion： Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the qual展开更多
以河南省漯河市、周口市和驻马店市交界处为研究区,基于2000年10月~2011年12月间的101幅图像,采用谐波模型和断点识别算法拟合Landsat时间序列实现对过火像元的检测,并将结果与目视解译结果、MODIS火烧迹地产品MCD64A1检测结果对比进行...以河南省漯河市、周口市和驻马店市交界处为研究区,基于2000年10月~2011年12月间的101幅图像,采用谐波模型和断点识别算法拟合Landsat时间序列实现对过火像元的检测,并将结果与目视解译结果、MODIS火烧迹地产品MCD64A1检测结果对比进行精度分析。结果表明:①随着燃烧面积指数BAI(Burned Area Index)异常值阈值增大,焚烧火点误判误差减小,漏判误差增大,火烧迹地制图的总体精度先增大后减小;②当BAI异常值阈值2.9×RMSE(Root Mean Square Error)时,该方法总体精度达到最高93.25%,MCD64A1产品总体精度为70.25%;③本文算法的漏判误差和误判误差相对平衡,而MCD64A1产品的漏判误差远大于误判误差。研究表明,相比MODIS火烧迹地产品数据,Landsat时间序列火烧迹地法可更有效地检测农田火烧迹地。展开更多
文摘Objective： In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene （rAd-p53） injection in patients with advanced non-small-cell lung cancer （NSCLC） in the combination with the therapy of bronchial arterial infusion （BAI）. Methods： A total of 58 patients with advanced NSCLC were enrolled in a non-randomized, two-armed clinical trial. Of which, 19 received a combination treatment of BAI and rAd-p53 （the combo group）, while the remaining 39 were treated with only BAI （the control group）. Patients were followed up for 12 months, with safety and local response evaluated by the National Cancer lnstitute＇s Common Toxicity Criteria and response evaluation criteria in solid tumor （RECIST）, respectively. Time to progression （TTP） and survival rates were also analyzed by Kaplan-Meier method. Results In the combo group, 19 patients received a total of 49 injections ofrAd-p53 and 46 times of BAI, respectively, while 39 patients in the control group received a total of 113 times of BAI. The combination treatment was found to have less adverse events such as anorexia, nausea and emesis, pain, and leucopenia （P〈0.05） but more arthralgia, fever, influenza-like symptom, and myalgia （P〈0.05）, compared with the control group. The overall response rates （complete response （CR）＋partial response （PR）） were 47.3% and 38.4% for the combo group and the control group, respectively （P〉0.05）. Patients in the combo group had a longer TTP than those in the control group （a median 7.75 vs 5.5 months, P-0.018）. However, the combination treatment did not lead to better survival, with survival rates at 3, 6, and 12 months in the combo group being 94.74%, 89.47%, and 52.63%, respectively, com- pared with 92.31%, 69.23%, and 38.83% in the control group （P=0.224）. Conclusion： Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the qual
文摘以河南省漯河市、周口市和驻马店市交界处为研究区,基于2000年10月~2011年12月间的101幅图像,采用谐波模型和断点识别算法拟合Landsat时间序列实现对过火像元的检测,并将结果与目视解译结果、MODIS火烧迹地产品MCD64A1检测结果对比进行精度分析。结果表明:①随着燃烧面积指数BAI(Burned Area Index)异常值阈值增大,焚烧火点误判误差减小,漏判误差增大,火烧迹地制图的总体精度先增大后减小;②当BAI异常值阈值2.9×RMSE(Root Mean Square Error)时,该方法总体精度达到最高93.25%,MCD64A1产品总体精度为70.25%;③本文算法的漏判误差和误判误差相对平衡,而MCD64A1产品的漏判误差远大于误判误差。研究表明,相比MODIS火烧迹地产品数据,Landsat时间序列火烧迹地法可更有效地检测农田火烧迹地。
